From diagnostic testing to discovery science, modelling and policy: the UCLH-Crick Legacy study
The COVID pandemic was the first global pandemic vaccination programme, and presented an opportunity to understand how immunity evolves after both infection and vaccination, and how this subsequently impacts viral evolution. The speaker will present how we have used data from the UCLH-Crick Legacy study to better understand how immunity evolves, and the modelling approach taken with Adam Kucharski’s team at LSHTM to investigate more effective vaccination boosting strategies.
Dr Emma Wall, Francis Crick Institute & University College London Hospitals Biomedical Research Centre
Dr Emma Wall is an academic consultant in Infectious Diseases and Acute Medicine. She holds a Senior Clinical Research Fellowship, jointly appointed between the Francis Crick Institute and UCLH Biomedical Research Centre. Emma the leads the Legacy study, a prospective observational cohort study investigating SARSCoV2 susceptibility, transmission and disease severity.
Emma is a co-investigator on the STIMULATE-ICP trial investigating the management and treatment of post-COVID syndrome, also known as Long COVID. She has developed a specialist interest in Long COVID, and has been working in the Post-COVID clinic since 2020. She is the lead for the nested drug trial within STIMULATE.
Emma graduated from the University of Bristol in 2000, following UK-based post-graduate training in medicine, she worked in Northern Australia, Uganda and Cambridge prior to higher specialist training in infection and internal medicine in North West London. Dr Wall did her PhD at the Liverpool School of Tropical Medicine and the Malawi Liverpool Wellcome Trust Clinical Research Programme in Malawi, studying clinical management and epidemiology of bacterial meningitis in Malawian adults. Prior to joining the Francis Crick Institute as a post-doctoral clinical fellow, she was a NIHR clinical lecturer in Infection at UCL. Her primary research interest is invasive infection in clinically vulnerable adults with a particular focus on host-pathogen interactions, neurological infection and improving clinical outcomes from infections caused by Streptococcus pneumoniae. More recently she has focussed on the evaluation of humoral and cell-mediated responses to COVID-19 vaccines and mild COVID infection in healthy adults and immunocompromised patient groups within the Legacy and STIMULATE-ICP studies.
- Please note that you can join this event in person or you can join the session remotely.
- Please note that the recording link will be listed on this page when available.